Intarcia Therapeutics
Hayward
About Intarcia Therapeutics
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $1.7B
- Funding stage: M&A
- Last round: Series Unknown (Aug 2019)
- Website: intarcia.com
- Phone: 617-936-2500
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical Device, Personal Health
Social Profiles
Canonical: https://fsome.com/organization/intarcia-therapeutics-43071 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.